Pluri Inc. (PLUR)
NASDAQ: PLUR
· Real-Time Price · USD
4.77
-0.05 (-1.04%)
At close: May 01, 2025, 3:42 PM
4.32
-9.43%
After-hours: May 01, 2025, 05:29 PM EDT
-1.04% (1D)
| Bid | 4.26 |
| Market Cap | 33.44M |
| Revenue (ttm) | 678K |
| Net Income (ttm) | -15.06M |
| EPS (ttm) | -3.68 |
| PE Ratio (ttm) | -1.3 |
| Forward PE | -1.98 |
| Analyst | n/a |
| Ask | 5 |
| Volume | 1,480 |
| Avg. Volume (20D) | 16,131 |
| Open | 4.98 |
| Previous Close | 4.82 |
| Day's Range | 4.77 - 5.00 |
| 52-Week Range | 3.33 - 7.13 |
| Beta | 1.96 |
About PLUR
Pluri Inc., a biotechnology company, focuses on the development of placenta-based cell therapy product candidates for the treatment of multiple inflammatory, muscle injuries, and hematologic conditions. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trials for the muscle recovery after surgery for hip fracture; in Phase II clinical trails for the treatment of acute respir...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 30, 2003
Employees 106
Stock Exchange NASDAQ
Ticker Symbol PLUR
Website https://pluri-biotech.com/
4 months ago
+4.76%
Pluri shares are trading higher after the company ...
Unlock content with
Pro Subscription
5 months ago
+11.84%
Brainstorm Cell Therapeutics and Pluri shares are trading higher after the companies entered into a memorandum of understanding to manufacture NurOwn for a Phase 3b trial in amyotrophic lateral sclerosis.
